中国实用儿科杂志2026，Vol.41Issue(2)：110-115,6.DOI:10.19538/j.ek2026020605
生物制剂在儿童支气管哮喘及共病治疗中的研究进展
Research progress of biologics in the treatment of bronchial asthma and comorbidities in children
摘要
Abstract
Allergic diseases are inflammatory diseases that cause tissue inflammation or organ dysfunction due to abnormal immune response to allergens,and the global health burden is huge,severely affecting the quality of life of the children.Despite great progress in the understanding of allergic diseases in recent years,especially bronchial asthma,it is found that there are significant differences in clinical characteristics(phenotype),treatment response,or disease progression in many children receiving conventional treatment.With the latest understanding of the pathophysiology of bronchial asthma,biologics provide new therapeutic strategies for severe,and also provide new approach difficult-to-control airway allergic diseases and prevent disease progression.Most of the current studies are conducted in bronchial asthma and show encouraging results.This article summarizes the clinical progress of the application of biologics in children's bronchial asthma and provides clinicians with relevant application information.关键词
儿童/支气管哮喘/生物制剂Key words
child/bronchial asthma/biologics分类
医药卫生引用本文复制引用
皇惠杰,向莉..生物制剂在儿童支气管哮喘及共病治疗中的研究进展[J].中国实用儿科杂志,2026,41(2):110-115,6.基金项目
国家儿童医学中心科技创新发展专项(ZHFY3-1-015) （ZHFY3-1-015）
北京市科技新星计划交叉合作课题(20240484542) （20240484542）
"生机计划2023"项目(202406170002) （202406170002）
